Ingo K. Mellinghoff is in the Departments of Medicine and Molecular and Medical Pharmacology, and Charles L. Sawyers is in the Departments of Medicine, Molecular and Medical Pharmacology and Urology, the Molecular Biology Institute, and the Howard Hughes Medical Institute, all at the David Geffen School of Medicine at UCLA, University of California, Los Angeles, California 90095-1678, USA. csawyers@mednet.ucla.edu
Cancer treatment is evolving from the empirical administration of chemotherapeutics to the precise deployment of molecularly targeted agents. This new paradigm depends on the ability to monitor therapy using molecular signatures of target inhibition in tumor tissue. Genetically engineered mice may prove useful for deriving such signatures, as shown for an analog of the anticancer drug rapamycin (pages 594−601).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
